BioMedNewsBreaks Archive - Page 92 of 251

TuesdayDec 12, 2023 11:00 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports on Preclinical Results from Psoriatic Human Skin Trial

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products, has announced successful preclinical trial results of its innovative anti–IL–17 VHH antibody (“NanoAb”). The trial evaluated Scinai's NanoAbs as a local treatment for the large and underserved population of mild to moderate plaque psoriasis. The study was conducted by Genoskin, a French biotechnology company. According to the announcement, Genoskin's human skin models were induced for expression of plaque psoriasis symptoms, thereby enabling ex–vivo examination of the therapeutic effects of drugs targeting underlying mechanisms in the pathogenesis of plaque psoriasis, specifically the…

MondayDec 11, 2023 12:31 pm

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announced Peer-Reviewed Journal Publishes Data Supporting NanoAbs

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products, is announcing the publication of a peer-reviewed article regarding NanoAbs. The article reports on data that supports the use of Scinai's aerosolized NanoAbs as a platform for the treatment of hyperinflammatory viral diseases, which addresses significant medical needs. Titled “Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters,” the article is published in the prominent “Antiviral Research” journal. According to the announcement, the article focused on a new generation of anti-SARS-CoV-2 NanoAbs, identified…

FridayDec 08, 2023 2:59 pm

BioMedNewsBreaks — Clene Inc.’s (NASDAQ: CLNN) Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS Patients

Clene (NASDAQ: CLNN), together with its wholly owned subsidiary Clene Nanomedicine Inc., recently provided operating highlights for its amyotrophic lateral sclerosis (“ALS”) clinical program. “In August, Clene reported a 24-month long-term data cut from the open-label extension (‘OLE’) of the RESCUE-ALS study as of July 2023, which showed a significant median survival benefit of 19.3 months in addition to a significant (p=0.049) 52% decreased risk of ALS clinical worsening events – defined as the first occurrence of death, tracheostomy (a procedure that involves creating an opening in the neck into the windpipe to help air and oxygen reach the lungs),…

ThursdayDec 07, 2023 1:08 pm

BioMedNewsBreaks — Branded Legacy Inc. (BLEG) Retires 400M Common Shares, Announces Other Key Moves to Enhance Shareholder Value

Branded Legacy (OTC: BLEG), a leader in the biotech industry, has retired an additional 400,000,000 shares of its common stock, bringing the total number of shares retired to two billion. According to the announcement, the retirement of these stocks marks a “significant move” in the company's commitment to enhancing shareholder value, which also includes a broader strategy to streamline share structure and improve market standing. The announcement also noted recent acquisitions that have contributed to increasing the company’s assets portfolio to more than $1 million this month. In the announcement, the company also noted that it has purchased ultraefficient analytical and chemical…

WednesdayDec 06, 2023 1:40 pm

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) CEO Featured in Just-Released Fireside Chat Video

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has released a fireside chat video with CEO and chair Howard Weisman. During the company update video, Weisman outlines the company’s recent achievement and reiterates PaxMedica’s focus on developing groundbreaking therapies and transformative solutions. Specifically, Weisman provided a summary of the company’s Oct. 25, 2023, FDA Type-B meeting, including the regulatory pathway for HAT-PAX-101. He also discussed the company’s successful $7 million public offering and the recent acquisition of suramin research assets from Rediscovery Life Sciences (“RLS”) as well as provided updates on the phase 3 trial…

WednesdayDec 06, 2023 1:28 pm

BioMedNewsBreaks — Astiva Health Partners with IBN to Deliver Corporate Communications, Increase Awareness

Astiva Health, a leading healthcare provider that specializes in delivering personalized and comprehensive healthcare solutions to diverse communities, has selected IBN, a versatile financial news and publishing company specializing in private and public entities, as a corporate communications partner. According to the announcement, the partnership is designed to enhance Astiva Health's corporate communications initiatives as the company focuses on its mission to deliver unparalleled quality care and establish enduring relationships within the community. Astiva Health is building a reputation for offering comprehensive healthcare solutions to diverse communities, with services rooted in a commitment to community-based healthcare and customized benefit packages aimed at…

WednesdayDec 06, 2023 12:36 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Interim Analysis on Global Berubicin Trial Showing Promising Results

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. In September, the company announced that 200 out of 243 expected patients had been enrolled in its ongoing study evaluating the effectiveness of Berubicin for recurrent glioblastoma (“GBM”), a highly aggressive and incurable form of brain cancer. The critical and adaptive global trial involves multiple centers and is open-label, randomized and controlled, comparing Berubicin to Lomustine - the standard of care - in adult patients with recurrent GBM (“WHO Grade IV”) after standard first-line therapy has failed. The…

TuesdayDec 05, 2023 4:36 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Closes Non-Brokered Private Placement

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) today announced that it has closed a non-brokered private placement and issued 24 class A multiple voting shares of the company, each at a price of $1.90, for gross proceeds of $45.60 (the “offering”). All securities issued pursuant to the offering are subject to a statutory hold period of four months plus a day from issuance in accordance with applicable securities laws of Canada. FSD Pharma intends to use the proceeds of the offering for general working capital purposes. To view the full press release, visit https://ibn.fm/NQ4uk About FSD Pharma Inc. FSD…

TuesdayDec 05, 2023 3:25 pm

BioMedNewsBreaks – SOHM, Inc. (SHMN) Announces 2024 Outlook for Business Units

SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, today announced its outlook for 2024 for each of its business units. SOHM is organized into the following business units: OTC Self-care (over-the-counter nutraceuticals and cosmeceuticals), Branded Generics (off-patent prescription pharmaceuticals), CDMO, Contract Development Manufacturing (contract manufacturing services), and ABBIE, Gene-editing Bio-kits. As detailed in the announcement, for each of these units, the company provided its outlook for the upcoming year along with relevant unit-specific status on: market backgrounds, business strategy and model, branding strategy, sales channels, and commercial status. To…

TuesdayDec 05, 2023 2:45 pm

BioMedNewsBreaks – Safety Shot (NASDAQ: SHOT) Releases Updated Report on Litigation

Safety Shot (NASDAQ: SHOT), makers of the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity, is reporting on its newly filed lawsuit against Capybara Research. According to the update, the company filed a federal lawsuit in the U.S. District Court for the Southern District of New York against Capybara Research on Dec. 4, 2023. In addition, the company is reporting that after weeks of investigatory work by counsel along with third-party assistance and cooperation, the person responsible for the malicious article has been identified. The company is now taking steps…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports on Preclinical Results from Psoriatic Human Skin Trial

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announced Peer-Reviewed Journal Publishes Data Supporting NanoAbs

BioMedNewsBreaks — Clene Inc.’s (NASDAQ: CLNN) Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS Patients

BioMedNewsBreaks — Branded Legacy Inc. (BLEG) Retires 400M Common Shares, Announces Other Key Moves to Enhance Shareholder Value

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) CEO Featured in Just-Released Fireside Chat Video

BioMedNewsBreaks — Astiva Health Partners with IBN to Deliver Corporate Communications, Increase Awareness

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Interim Analysis on Global Berubicin Trial Showing Promising Results

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Closes Non-Brokered Private Placement

BioMedNewsBreaks – SOHM, Inc. (SHMN) Announces 2024 Outlook for Business Units

BioMedNewsBreaks – Safety Shot (NASDAQ: SHOT) Releases Updated Report on Litigation

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search